FCC Approves Charter Communications’ $34.5 Billion Acquisition of Cox Communications 
Rio Tinto Advances Gallium Extraction Project in Canada with Federal Funding Support 
Boeing Secures $166.8 Million U.S. Navy Contract for P-8A Engineering and Software Support 
Paramount Skydance to Acquire Warner Bros Discovery in $110 Billion Media Mega-Deal 
Australia Targets AI Platforms With Strict Age Verification Rules 
Lynas Rare Earths Shares Surge 7% After Malaysia Renews Processing Plant Licence for 10 Years 
Qantas Shares Plunge 10% as Iran Strikes Send Oil Prices Soaring and Disrupt Global Flights 
United Airlines Boeing 787-9 Makes Emergency Landing in Los Angeles After Possible Engine Fire 
Flare, Xaman Roll Out One-Click DeFi Vault for XRP Yield via XRPL Wallets 
Samsung Electronics Stock Poised for $1 Trillion Valuation Amid AI and Memory Boom 
Malta will gain from smart heritage 
Trump Media Weighs Truth Social Spin-Off Amid $6B Fusion Energy Pivot 
AWS Data Center in UAE Hit by Fire After Objects Strike Facility Amid Regional Tensions 
APEX Tech Acquisition Inc. Raises $111.97 Million in NYSE IPO Under Ticker TRADU 
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade 
Toyota Raises Toyota Industries Buyout Offer Amid Governance Concerns 
CVS Health is projecting another year of solid earnings growth, announcing that its expected 2026 profit will surpass both Wall Street forecasts and its own 2025 earnings outlook. The update, shared during the company’s investor day, underscores the steady progress of its ongoing turnaround strategy led by Chief Executive David Joyner.
Joyner emphasized that CVS has delivered on its commitments throughout the year and will now concentrate on improving consumer experiences and rebuilding trust—an area he described as a major challenge in today’s healthcare marketplace. As part of this effort, the company unveiled a new consumer app designed to integrate CVS services and offer new revenue opportunities for partners.
Shares of CVS climbed nearly 5% to $80.17 in morning trading following the announcement, extending a year of strong market performance. The stock has surged more than 70% in 2025 as the company implemented sweeping changes, including cost reductions, exits from underperforming markets, and enhancements to leadership to restore investor confidence.
Chief Financial Officer Brian Newman highlighted the company’s strong finish to 2025, stating that CVS expects “another year of strong earnings growth in 2026.” The company forecast adjusted earnings between $7.00 and $7.20 per share for 2026, slightly above consensus expectations of $7.16 per share.
While CVS anticipates up to $400 billion in revenue next year—short of analysts’ projected $419.26 billion—the company expects growth momentum to be driven by improved margins in its Aetna insurance arm and CVS Caremark pharmacy benefit management business. CVS also reiterated plans to exit the Affordable Care Act insurance market in 2026 due to rising medical costs.
Additionally, CVS raised its 2025 profit guidance to between $6.60 and $6.70 per share, marking its fourth increase this year. Analysts at Leerink Partners noted that CVS’ near-term performance supports a strong long-term recovery story for the healthcare conglomerate.
